The takeaway
For adults with type 2 diabetes, adding semaglutide while reducing basal insulin improved weight and blood-sugar results compared with increasing basal insulin alone.
What did researchers test?
The 40-week trial randomized 573 adults with overweight using basal insulin. One group added weekly semaglutide 2.0 mg with supervised insulin reductions; the other had insulin glargine adjusted toward glucose targets.
Kilograms; supervised treatment strategies
Original visual based on the study.
| Group or measure | Result |
|---|---|
| Semaglutide 2 mg plus reduced insulin | −8.0 kg |
| Titrated insulin glargine | +0.5 kg |
What changed?
Average weight fell 8.0 kg with semaglutide plus reduced insulin, versus a 0.5 kg gain with insulin adjustment alone. The between-group difference was 8.5 kg, not the amount everyone lost. Blood-sugar control also improved more with the combination strategy.
What were the trade-offs?
Digestive problems affected 106 participants in the combination group versus 19 in the comparison group. Side effects led 3.5% versus 0.4% to stop treatment.
What does this mean for you?
This was a supervised treatment strategy, not a reason to reduce insulin yourself. Participants started on no more than 40 units daily; results may differ with higher insulin needs. The trial was open-label, and some insulin-use records were missing. Novo Nordisk funded it.